Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

NCT06004388 | Completed Phase 3 DMC FDA Device

• 1 other identifier: CT-132-R-002
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

Conditions

Migraine; Episodic Migraine; Headache; Headache, Migraine

Keywords

Prescription digital therapeutic (PDT); Software as a Medical Device (SaMD); Smartphone app; CGRP; Calcitonin Gene-Related Peptide Inhibitor Therapy

Outcome Measures

Primary Outcomes (1)

• Change in Monthly Migraine Days (MMDs)

  Change from baseline in the number of Monthly Migraine Days (MMDs) at Week 12

  Baseline to Week 12

Secondary Outcomes (9)

• Proportion of Patients with Decrease in MMDs

  Baseline to Week 12

• Change in MMDs at Weeks 4 and 8

  Baseline to Weeks 4 and 8

• Change in Mean MMDs

  Baseline to Week 12

• Change in Average Headache Severity

  Run-in to Weeks 9-12

• Change in Migraine Questionnaire

  Baseline to Weeks 4, 8 and 12

Study Arms (2)

ReMMiD-C Therapeutic Arm A

EXPERIMENTAL

Mobile application A (ReMMiD-C Digital Therapeutic) as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.

Device: Click Digital Therapeutic

ReMMiD-C Therapeutic Arm B

EXPERIMENTAL

Mobile application B as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.

Device: Click Digital Therapeutic

Interventions

Click Digital Therapeutic DEVICE

Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

ReMMiD-C Therapeutic Arm A; ReMMiD-C Therapeutic Arm B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A participant will be eligible for entry into the study if all of the following criteria are met per participant self-report:
• Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.
• Lives in the United States.
• Adult or late adolescent, ≥ 18 years of age at the time of informed consent.
• Able to read and understand the English informed consent form.
• The following will be investigator-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD), 3rd Edition:
• i. Age of onset of migraines prior to 50 years of age
• ii. Migraine attacks, on average, lasting 4-72 hours if untreated
• iii. Per participant report, 4 or more migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days)
• iv. Four to fourteen migraine days during the run-in period
• Is currently managing migraines with at least 1 prescription CGRP inhibitor therapy for the preventive or acute treatment of episodic or chronic migraine during the 3 months prior to screening.
• Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later, and is willing to download and use the specified eDiary and Study App required by the protocol.
• Is willing and able to receive SMS text messages and push messages on their smartphone.
• Is the owner of, and has regular access to, an email address.
• Has regular access to the Internet via cellular data plan and/or wifi.

You may not qualify if:

• A participant will not be eligible for study entry if any of the following criteria are met per participant self-report:
• History of basilar migraine or hemiplegic migraine.
• Active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or complex regional pain syndrome (CRPS).
• Other pain syndromes (including trigeminal neuralgia), psychiatric conditions (such as current major depressive episode, bipolar disorder, major depressive disorder, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.
• History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months (48 weeks) or having met DSM-5 criteria for any significant substance use disorder within the past 12 months (48 weeks) from the date of the screening visit.
• History of use of analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or acetaminophen, including opioids) or butalbital on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit or during the run-in period.
• Post-traumatic headache, persistent post-traumatic headache, or post-concussion syndrome.
• Other significant acute or chronic medical condition(s) that, in the opinion of the Investigator, may confound the interpretation of findings to inform PDT development.
• Failure to adhere with or inability to complete eDiary inputs and onboarding activities during the run-in period. Participants who are not adherent during the run-in period are not eligible for study entry.
• Previous enrollment in any digital therapeutics pilot or pivotal study for a migraine indication.
• Participation in any other investigational clinical study

Sponsors & Collaborators

• Click Therapeutics, Inc.: lead

Study Sites (1)

Click Therapeutics

New York, New York, 10013, United States

Location

MeSH Terms

Conditions

Migraine Disorders; Headache

Condition Hierarchy (Ancestors)

Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Shaheen Lakhan

  Click Therapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Double-blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 26, 2023
• First Posted: August 22, 2023
• Study Start: July 21, 2023
• Primary Completion: May 21, 2024
• Study Completion: June 5, 2024
• Last Updated: December 18, 2024

Record last verified: 2024-03

Locations

US (1)